The Impact of Discrepancy between Measured versus Stated Weight on Hemorrhagic Transformation and Clinical Outcomes after Intravenous Alteplase Thrombolysis
Explore this paper's citation graph
Summary
More alteplase usage than actual weight led to higher hemorrhagic transformation and as one of the predictors for clinical deterioration, it is important to administrate altePlase based on an accurately measured weight.
- Type
- article
- Published
- 2017-08-26
- Cited by
- 1
- References
- 33
- OpenAlex
- https://openalex.org/W2748439972
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:3598696
Keywords
Medicine, Interquartile range, Thrombolysis, Stroke (engine), Internal medicine
References
- Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.
- Current Status of Intravenous Thrombolysis for Acute Ischemic Stroke in Asia
- Post-Thrombolytic Hyperglycemia and 3-Month Outcome in Acute Ischemic Stroke
- Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis
- Prediction of long-term outcome in the early hours following acute ischemic stroke. Italian Acute Stroke Study Group.
- Urgent Therapy for Stroke: Part I. Pilot Study of Tissue Plasminogen Activator Administered Within 90 Minutes
- Low-Dose Tissue Plasminogen Activator and Standard-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke in Asian Populations: A Review
- Thrombolysis With 0.6 mg/kg Intravenous Alteplase for Acute Ischemic Stroke in Routine Clinical Practice: The Japan post-Marketing Alteplase Registration Study (J-MARS)
- Baseline NIH Stroke Scale score strongly predicts outcome after stroke
- Effects of Admission Hyperglycemia on Stroke Outcome in Reperfused Tissue Plasminogen Activator–Treated Patients
- Impact of Fasting Glycemia and Regional Cerebral Perfusion in Diabetic Subjects: A Study With Technetium-99m-Ethyl Cysteinate Dimer Single Photon Emission Computed Tomography
- Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom Onset: The ATLANTIS Study: A Randomized Controlled Trial
- Symptomatic intracranial hemorrhage after stroke thrombolysis: The SEDAN Score
- Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.
- Age and National Institutes of Health Stroke Scale Score Within 6 Hours After Onset Are Accurate Predictors of Outcome After Cerebral Ischemia: Development and External Validation of Prognostic Models
- Diabetes Mellitus, Acute Hyperglycemia, and Ischemic Stroke
- Insulin Resistance Is Associated With a Poor Response to Intravenous Thrombolysis in Acute Ischemic Stroke
- Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)
- Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials.
- Management of Hyperglycemia in Acute Stroke: How, When, and for Whom?
Cited by
Related papers
- The role of thrombolysis in the management of thromboembolic disorders: a four-year review.
- Effect of intravenous thrombolysis of Alteplase in treatment of acute ischemic stroke
- 效果热门在有干燥眼睛疾病的病人的角膜的内皮细胞层上的 0.05% cyclosporine A
- [Therapeutic assessment between the thrombolysis in 6 hours and delayed thrombolysis after onset of acute myocardial infarction].
- Hemoglobin Levels Across the Pediatric Critical Care Spectrum: A Point Prevalence Study*
- Prognostic value of proadrenomedullin in patients with COVID-19 pneumonia
- Timeliness of Intravenous Thrombolysis via Telestroke in Georgia
- Hospitalization Costs for Acute Ischemic Stroke Patients Treated With Intravenous Thrombolysis in the United States Are Substantially Higher Than Medicare Payments